Sudhir Agrawal, PhD, FRSC is a visiting professor in the department of medicine at the University of Massachusetts Medical School, a member of the Business Advisory Board of Harvard Medical School’s Initiative for RNA Medicine, and an advisory board member for Lytix Biopharma. Sudhir is founder and member of Arnay Sciences LLC, as well as founder of Idera Pharmaceuticals where he held various leadership roles within the company, including chairman, CEO, president of research, and chief scientific officer.

Sudhir’s research interests focus on the discovery and development of nucleic acid therapeutics, including antisense oligonucleotides (ASOs). He has edited four books about oligonucleotides and antisense technology, published hundreds of research papers, and is listed as a co-inventor of more than 400 patents worldwide.